153380-43-9Relevant academic research and scientific papers
Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere
Mimoto, Tsutomu,Hattori, Naoko,Takaku, Haruo,Kisanuki, Sumitsugu,Fukazawa, Tominaga,Terashima, Keisuke,Kato, Ryohei,Nojima, Satoshi,Misawa, Satoru,Ueno, Takamasa,Imai, Junya,Enomoto, Hiroshi,Tanaka, Shigeki,Sakikawa, Hiroshi,Shintani, Makoto,Hayashi, Hideya,Kiso, Yoshiaki
, p. 1310 - 1326 (2007/10/03)
We designed and synthesized a new class of peptidomimetic human immunodeficiency virus protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid], with a hydroxymethylcarbonyl isostere as the active moiety. From a structure-activity relationship study of HIV-1 protease inhibition, enzyme selectivity for other aspartyl proteases, the antiviral activity and pharmacokinetics in rats, 24c (KNI-227) and 24d (KNI-272, our first clinical candidate) were found to be selective and orally potent HIV protease inhibitors. Moreover, an improvement of the pharmacokinetic features of KNI-272 provided two long-lasting and highly bioavailable compounds (24g: JE-2178,h: JE-2179).
Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120
Asagarasu, Akira,Uchiyama, Taketo,Achiwa, Kazuo
, p. 697 - 703 (2007/10/03)
Some HIV-protease inhibitor derivatives having an N- carbomethoxycarbonyl-prolyl-phenylalanine benzyl ester (CPF) moiety as a binding site to gp120 were designed and synthesized. Almost all the compounds bearing CPF on the phenoxyacetyl group showed protease-inhibitory activity. Compounds 25a and 25b, which have the CPF moiety at the ortho- and meta- positions of the phenoxyacetyl group, respectively, had anti-HIV activity, although the others showed only protease-inhibitory activity. These results suggest that 25b binds to gp120 and inhibits HIV protease.
Synthesis of dipeptide-type human immunodeficiency virus (HIV) protease inhibitors with a binding unit to GP120
Asagarasu, Akira,Takayanagi, Nao,Achiwa, Kazuo
, p. 867 - 870 (2007/10/03)
Some dipeptide-type human immunodeficiency virus (HIV) protease inhibitors derived from KNI-102, with a N-carbomethoxycarbonylprolyl- phenylalanine benzyl ester (CPF) moiety as a binding site to gp120, were synthesized. Compounds 11a showed 7 - 100 times higher HIV protease- inhibitory activity (11a; IC50 = 0.90 μg/ml, 1.1 μM) than the standard compound 3 or 4 (3; IC50 = 3.7 μg/ml, 7.7 μM, 4; IC50 = 75 μg/ml, 155 μM). Generally, the compounds substituted at the o-position of the phenoxyacetyl group 7a, 11a, 16a and 21a showed several times higher inhibitory activity than 3.
Inhibitors of HIV protease
-
, (2008/06/13)
Compounds of formula (I): STR1 wherein: R1 is hydrogen, alkyl, aralkyl, --CORa, --CORb, --CSRa, --CSRb, --SO2 Rb, --CONHRb, --CSNHRb, --CONRb Rb or --CSNRb Rb ; R2 is hydrogen or alkyl; R3 is hydrogen, alkylidene, substituted alkyl, or Rb ; R4 is optionally substituted alkyl, cycloalkyl, or aryl; R5 is Rb O--, Rb Rb N--, Rb HN--, aralkyloxycarbonyloxy or aralkyloxycarbonylamino, or R5 is --(CH2)p --D--(CH2)r --, where D is a single bond, carbonyl, oxygen, sulfur, --NH--, --(CH2 =CH2)-- or --NHCO--; and p and r are each 0 or an integer from 1 to 5; A is --(CH2)m --B--(CH2)n -- where B is a single bond, carbonyl, oxygen, sulfur, --NH--, --(CH2 =CH2)-- or --NHCO--; and m and n are each 0 or an integer from 1 to 5; Ra is alkoxy, aralkyloxy, aryloxy or alkoxycarbonyl; Rb is optionally substituted alkyl, cycloalkyl, heterocyclic, aryl or arylalkenyl; and pharmaceutically acceptable salts and esters thereof and pro-drugs therefor, have the ability to inhibit the activity of HIV protease and may thus be used for the treatment and prophylaxis of AIDS.
Synthesis and human immunodeficiency virus (HIV-1 protease inhibitory activity of tripeptide analogues containing a dioxoethylene moiety
Kitazaki,Asano,Kato,Kishimoto,Itoh
, p. 2636 - 2640 (2007/10/02)
Tripeptide analogues 2 and 3 containing a dioxoethylene moiety were designed based on the characteristic structure of the naturally occurring human immunodeficiency virus (HIV)-I protease inhibitors RPI-856 A, B, C and D (1). The compounds (2, 3) prepared showed high inhibitory activity, comparable to that of RPI-856 A, against HIV-1 protease in vitro.
KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic
Mimoto,Imai,Tanaka,Hattori,Kisanuki,Akaji,Kiso
, p. 3088 - 3088 (2007/10/02)
HIV-1 protease inhibitors containing allophenylnorstatine (Apns; (2S,3S)-3-amino-2-hydroxy-4-phenyl-butyric acid]-Pro (syn distereomer) as a transition-state mimic were established to be potent and highly selective. Z-Asn-Apns-Pro-NHBu(t) (KNI-102) is the only tripeptide exhibiting substantial anti-HIV activity and may be of minimum size for potent, selective inhibition of HIV protease. Ready availability due to its simple chemical structure and stability should make it valuable for studies of the development of metabolically stable anti-AIDS drugs.
